The US Supreme Court will decide a case involving 2 insurance companies that claimed they were shorted $12 billion by the federal government for "risk corridor" payments related to the ACA; Missouri's last abortion clinic will stay open until at least Friday after a state circuit court judge extended a preliminary injunction he previously issued; City of Hope will invest $1 billion in a new cancer research center and hospital in Irvine, California.
Yesterday, the US Supreme Court agreed to decide whether Congress acted correctly when it failed to fully fund “risk corridors,” financial protections that were offered to health insurers that took part in marketplaces under the Affordable Care Act (ACA), according to The New York Times. In their brief, insurers said they were victims of a massive “bait and switch,” and the government paid them $12 billion less than what they were promised. Some companies that were paid less than promised have since gone bankrupt. The Supreme Court will hear consoldiated suits after a divided 3-judge appellate panel ruled against the insurance companies last year.
Missouri Circuit Court Judge Michael Stelzer ruled yesterday that the state’s only abortion clinic can continue performing abortions through Friday, The New York Times reported. Stelzer extended a preliminary injunction he previously issued to give the clinic time to take a licensing fight before an administrative panel. The clinic will be forced to shut down if its license isn’t renewed and would make Missouri the first state since 1974 to lack a facility where abortions can be performed.
City of Hope will invest $1 billion in a new hospital and research center focused on cancer care in Irvine, California, the Los Angeles Times reported. Without convenient access to care, about 20% of Orange County patients have previously been forced to travel long distances to seek care elsewhere. City of Hope expects to convert an unused building on recently purchased property into a research center by 2021, and to complete construction on the hospital by 2025.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More